Elecsys® Troponin T hs Gen 6

IVD For in vitro diagnostic use.
Elecsys<sup>®</sup> Troponin T hs Gen 6
Contact us
A woman experiencing chest pain after exercise indicates a potential for Elecsys Trop T version 6 testing

Elecsys® Troponin T hs Gen 6: ACS care with unprecedented diagnostic confidence

As one of the top three reasons for emergency care visits chest pain represents a significant burden on healthcare services.1 Yet only one in every ten patients will actually be experiencing a heart attack.2 The ability to quickly and reliably identify those patients who are suffering from acute myocardial infarction (AMI) is crucial in ensuring the best possible outcomes and protecting overstretched healthcare services.

High-sensitive Troponin T is a well-established and guideline-recommended biomarker for diagnosing acute coronary syndrome (ACS).3 With a 30-year legacy in troponin innovation, Roche was the first company in the world to introduce high-sensitivity troponin tests, and the first to receive FDA approval.4-12 Building on this legacy, the Elecsys Troponin T hs Gen 6 (TnT hs Gen 6) assay sets a new benchmark in terms of precision, robustness, and global validation.13

TnT hs Gen 6 test enables clinicians to detect even the smallest changes in troponin levels—a critical biomarker for the diagnosis of ACS—with high confidence.14 This ensures that in a situation when every second counts, patients receive the life-saving care they need at the earliest opportunity.

Benefits at a glance

Benefits at a glance

An icon of a test tube with a checkmark, representing the precision of Elecsys cardiac Troponin T hs Gen 6 (TnT hs Gen 6)

High sensitivity at even lower troponin levels for accurate, timely results, helping to boost confidence in decision-making and enhance triage efficiency.13,14

Elecsys TnT hs Gen 6 exceeds the latest high-sensitivity IFCC criteria, demonstrating leading standards in accuracy, sensitivity, and reliability.13-15

An icon of multiple test tubes, representing the robustness of Elecsys cardiac Troponin T hs Gen 6 (TnT hs Gen 6)
  • 10x more resistance to interferences from hemoglobin, for less resampling14,16
  • Low lot-to-lot and platform variability, demonstrating robustness and reproducibility, regardless of the analyzer or setting13,14
  • 3-level quality control13,14
  • Long-term compliance with current regulatory standards (National Institute of Standards and Technology reference materials), enhancing traceability and confidence in results14
An icon of a clipboard with a checkmark, representing the validation of Elecsys cardiac Troponin T hs Gen 6 (TnT hs Gen 6)

TSIX is the first global study program to establish and validate one diagnostic cutoff that works across diverse populations, settings, genders, and sample types.17

A globe icon, illustrating the global study to validate one diagnostic cutoff of Elecsys cardiac Troponin T hs Gen 6

4147 study subjects

An icon of a couple illustrating the one overall diagnostic cutoff of Elecsys cardiac Troponin T T hs Gen 6 assay

Overall

27 ng/L

An icon of a woman’s head illustrating the female diagnostic cutoff of Elecsys cardiac Troponin T T hs Gen 6 assay

Female

18 ng/L

An icon of a man’s head illustrating the male diagnostic cutoff of Elecsys cardiac Troponin T T hs Gen 6 assay

Male

32 ng/L

The cutoff enables standardized interpretation of troponin results worldwide and helps to simplify use compared to assays with varying sample type cutoffs.17

Related categories

Use left and right arrow keys to scroll between the tabs

Overview

Ordering Information

Technical Documents

Access important product documentation including relevant certificates and other resources.

After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
Document repository artboard
error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Compatible products

...
    ...

    Related products

    ...
      ...

      What our customers say

      The PERFORM-TSIX study is by far the largest, most global, and comprehensive study ever conducted for launching a new cardiovascular biomarker test. This highlights Roche's ambition to enable personalized cardiovascular care on a global scale.

      Prof. Dr. Raphael Twerenbold
      Interventional cardiologist and biomarker trialist at University Heart & Vascular Center, Hamburg, Germany

      Contact us

      Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

      Contact us

      References

      1. Weiss AJ, Jiang J. Agency for Healthcare Research and Quality, Most Frequent Reasons for Emergency Department Visits. 2018. Available from: https://hcup-us.ahrq.gov/reports/statbriefs/sb286-ED-Frequent-Conditions-2018.pdf
      2. Fanaroff AC et al. Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. JAMA. 2015 Nov 10;314(18):1955-65.
      3. European Society of Cardiology. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023 Aug 25;44:3720–3826.
      4. Collinson P. Update on global conversion to high sensitivity cardiac troponin assays. J Lab Precis Med. 2023 Apr 30;8:15.
      5. F. Hoffmann-La Roche Ltd. Elecsys Troponin T Gen 5 and Troponin T Gen 5 STAT Method Sheets.
      6. Chew D et al. A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes. Circulation. 2019 Nov 5;140(19):1543–56.
      7. Stoyanov K et al. RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction. Eur Heart J Acute Cardio Care. 2020 Feb;9(1):39–51.
      8. Twerenbold, R. et al. Outcome of Applying the ESC 0 /1-hour Algorithm in Patients With Suspected Myocardial Infarction. JACC. 2019 Jul 30;74:483–94.
      9. Danese et al. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med. 2016 May;4(10):194.
      10. Reichlin T et al. One-Hour Rule-out and Rule-in of Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin T. Arch Intern Med. 2012 Sep 10;172(16):1211–8.
      11. Reichlin T et al. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. CMAJ. 2015 May 19;187(8):E243–52.
      12. Mueller C et al. Multicenter Evaluation of a 0-Hour /1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Ann Emerg Med. 2016Jul;68(1):76–87.
      13. F. Hoffmann-La Roche Ltd. Knoll M et al. Manuscript in preparation. Data on file.
      14. F. Hoffmann-La Roche Ltd. Elecsys Troponin T hs Gen 6 Method Sheet. (v1.0). 2025.
      15. Apple FS et al. Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care Clinical chemistry. 2017 Jan;63(1):73-81.
      16. F. Hoffmann-La Roche Ltd. Elecsys Troponin T hs 09315357190 Method Sheet (v4.0). 2024.
      17. F. Hoffmann-La Roche Ltd. Daniels et al. Establishing reference values in healthy participants for a next generation cardiac Troponin T high sensitivity assay – The REF-TSIX Global Reference Study, in preparation. Data on file.